SYK - Stryker Corporation
After hours:
Chart Events
Double Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 272.40 |
| Open | 273.09 |
| Bid | 260.00 x 900 |
| Ask | 272.42 x 2900 |
| Day's Range | 271.33 - 275.85 |
| 52 Week Range | 188.84 - 306.56 |
| Volume | |
| Avg. Volume | 1,258,485 |
| Market Cap | 103.474B |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | 39.68 |
| EPS (TTM) | 6.87 |
| Earnings Date | Jul 24, 2023 - Jul 28, 2023 |
| Forward Dividend & Yield | 3.00 (1.10%) |
| Ex-Dividend Date | Jun 29, 2023 |
| 1y Target Est | 313.82 |
Fair Value
Related Research
ZacksTop Analyst Reports for Apple, Chevron & Accenture
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Chevron Corporation (CVX) and Accenture plc (ACN).
ZacksHere's Why You Should Retain Stryker (SYK) Stock for Now
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Business WireSurgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software
LEESBURG, Va., May 24, 2023--Stryker launches Q Guidance System with Cranial Guidance Software, providing groundbreaking planning and guidance capabilities.
Zacks3 Healthcare Trends to Ride for Longevity
Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.
ZacksHLN or SYK: Which Is the Better Value Stock Right Now?
HLN vs. SYK: Which Stock Is the Better Value Option?
Barrons.comHealthcare Stocks Are on Sale. Pfizer and Stryker Have Strong Growth Prospects.
Healthcare has had the greatest earnings growth of any sector since the mid-1980s. Why Pfizer and Stryker are two favorite stocks of the Jensen Quality Growth fund.
Motley FoolWhich Is the Safer Dividend Stock: Stryker or Medtronic?
Stryker (NYSE: SYK) and Medtronic (NYSE: MDT) are a pair of the biggest and most important medical-device and supply companies out there, but they're a bit different in the stability of the dividend income they offer to investors. Overall, Stryker's business is quite stable: It makes medical equipment, medical instruments, and surgical robotics for healthcare systems worldwide, and there isn't much in the way of rapidly shifting demand for its major segments. But it can reliably generate growth by investing in research and development (R&D) to make incremental improvements to its existing products, even if that growth is unlikely to be rapid due to the slow-growing nature of its markets. For example, developing more-advanced hip replacement products for use with its surgical robot system probably won't make investors rich overnight, but it'll keep the top and bottom lines expanding.
GlobeNewswireStryker declares a $0.75 per share quarterly dividend
Kalamazoo, Michigan, May 10, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable July 31, 2023 to shareholders of record at the close of business on June 30, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company
ZacksZacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
Zacks4 Medical Products Stocks to Capitalize on the Industry's Recovery
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
The Wall Street JournalMedical Device Maker Stryker Faces New Bribery Concerns
The medical-device maker disclosed an investigation by U.S. authorities into potential violations of antibribery law, the third such probe into the company in the past decade.
Motley FoolGot $5,000? Buy These 2 Stalwart Stocks and Hold Them Forever
Packing your portfolio with risky hyper-growth stocks might make you feel like a genius during a bull market, but when there's a downturn, your smile just might get turned upside down. As exciting as seeing rapidly rising share prices might be, your portfolio needs to be well-diversified, and that means you need a few companies that are stable in the face of turmoil, not to mention being capable of delivering some growth all the time. Thermo Fisher Scientific (NYSE: TMO) is a sturdy stock that's fit for holding for decades because it's one of the businesses that makes the entire biopharma sector run.
BenzingaWhat's Going On With Stryker Stock Today
The orthopedic and surgical device giant Stryker Corporation (NYSE: SYK) stock is trading lower despite reporting Q1 earnings beat and an upbeat outlook. It reported Q1 sales of $4.80 billion, up 11.8% Y/Y (+14% in constant currency), beating the consensus of $4.56 billion. Organic net sales increased 13.6% in the quarter, including 12.9% from increased unit volume and 0.7% from higher prices. MedSurg and Neurotechnology net sales of $2.7 billion increased by 11.0% (+13.1% in constant currency).
ZacksBAX vs. SYK: Which Stock Should Value Investors Buy Now?
BAX vs. SYK: Which Stock Is the Better Value Option?
PR NewswireStryker completes acquisition of Cerus Endovascular
Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular's CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will expand Stryker's current portfolio of aneur
ZacksStryker (SYK) Q1 Earnings Beat Estimates, Volume Improves
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
ZacksStryker (SYK) Tops Q1 Earnings and Revenue Estimates
Stryker (SYK) delivered earnings and revenue surprises of 7% and 4.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
Stryker lifts profit forecast on robust demand for devices
Medical technology company Stryker Corp on Monday raised its full-year profit forecast, citing stronger demand for the company's surgical devices. Device makers, lately, have been reporting a recovery in sales as staff shortages ease and procedure volumes pick up in hospitals. Last week, peer Edwards Lifesciences Corp raised its sales and profit forecasts for 2023, citing strong demand for the company's artificial heart valves.
- GlobeNewswire
Stryker reports first quarter 2023 operating results
Kalamazoo, Michigan, May 01, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2023: First Quarter Results Reported net sales increased 11.8% to $4.8 billionOrganic net sales increased 13.6%Reported operating income margin of 15.4%Adjusted operating income margin(1) contracted 70 bps to 21.1%Reported EPS increased 83.3% to $1.54Adjusted EPS(1) increased 8.6% to $2.14 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant
Motley Fool3 Medical Device Stocks Outpacing the Healthcare Industry This Year
Medical device makers are outperforming the general healthcare market so far this year as supply issues ease and the volume of medical procedures is increasing. Three examples are Medtronic (NYSE: MDT), Edwards Lifesciences (NYSE: EW), and Stryker (NYSE: SYK), each of which is up more than 15% this year. The rest of the healthcare industry, on the other hand, has mostly seen its shares decline.
Motley FoolThese 3 Stocks Might Be Getting a Little Too Expensive
Its valuation should be very attractive or at least reasonable -- otherwise you may buy at such a steep valuation that the stock will be as likely to retreat as to advance. Here are three promising companies whose stocks seem to have gotten ahead of themselves. Hershey (NYSE: HSY) has been a sweet investment for many people, outpacing the S&P 500 over the past decade with an average annual total return of roughly 14% versus 12% for the benchmark index.
ZacksStryker (SYK) to Report Q1 Earnings: What's in the Cards?
Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.
ZacksHere's How Much a $1000 Investment in Stryker Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
ZacksHAE vs. SYK: Which Stock Is the Better Value Option?
HAE vs. SYK: Which Stock Is the Better Value Option?
The Wall Street JournalMedical-Device Makers Gain Amid Return to Normalcy
Stryker, Edwards Lifesciences and Boston Scientific shares outperform the broader healthcare sector as procedure volumes rebound and costs stabilize.